{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:39:18Z","timestamp":1791308358171,"version":"4.3.1"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["KW\/1592\/CIZ\/001\/013\/001"],"award-info":[{"award-number":["KW\/1592\/CIZ\/001\/013\/001"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background<\/jats:title><jats:p>The use of single-tablet regimens (STRs) in HIV treatment is ubiquitous. However, reintroducing the (generic) components as multi-tablet regimens (MTRs) could be an interesting cost-reducing strategy. It is essential to involve patient-reported outcome measures (PROs) to examine the effects of such an approach. Hence, this study compared PROs of people living with HIV taking an STR versus a MTR in a real world setting.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Materials and methods<\/jats:title><jats:p>This longitudinal study included 188 people living with HIV. 132 remained on a MTR and 56 switched to an STR. At baseline, months 1-3-6-12-18 and 24, participants filled in questionnaires on health-related quality of life (HRQoL), depressive symptoms, HIV symptoms, neurocognitive complaints (NCC), treatment satisfaction and adherence. Generalized linear mixed models and generalized estimation equations mixed models were built.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Results<\/jats:title><jats:p>Clinical parameters and PROs of the two groups were comparable at baseline. Neurocognitive complaints and treatment satisfaction did differ over time among the groups. In the STR-group, the odds of having NCC increased monthly by 4,1% as compared to the MTR-group (p = 0.035). Moreover, people taking an STR were more satisfied with their treatment after 6 months: the median change score was high: 24 (IQR 7,5\u201329). Further, treatment satisfaction showed a contrary evolution in the groups: the estimated state score of the STR-group increased by 3,3 while it decreased by 0,2 in the MTR-group (p = 0.003). No differences over time between the groups were observed with regard to HRQoL, HIV symptoms, depressive symptoms and adherence.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Conclusions<\/jats:title><jats:p>Neurocognitive complaints were more frequently reported among people on an STR versus MTR. This finding contrasts with the higher treatment satisfaction in the STR-group over time. The long-term effects of both PROs should guide the decision-making on STRs vs. (generic) MTRs.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0262533","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T18:59:10Z","timestamp":1642100350000},"page":"e0262533","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens: Data from a real-life setting"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5482-0926","authenticated-orcid":true,"given":"Sophie","family":"Degroote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linos","family":"Vandekerckhove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Vogelaers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Vanden Bulcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"issue":"Suppl 3","key":"pone.0262533.ref001","first-page":"24S","article-title":"Single-Tablet Regimens in the Treatment of HIV-1 Infection","volume":"33","author":"J Cutrell","year":"2016","journal-title":"Federal practitioner: for the health care professionals of the VA, DoD, and PHS"},{"key":"pone.0262533.ref002","doi-asserted-by":"crossref","DOI":"10.1177\/2050312118816919","article-title":"HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens","volume":"6","author":"SN Kapadia","year":"2018","journal-title":"Sage Open Med"},{"issue":"8","key":"pone.0262533.ref003","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/09540121.2018.1442554","article-title":"Single tablet HIV regimens facilitate virologic suppression and retention in care among treatment naive patients","volume":"30","author":"V Hemmige","year":"2018","journal-title":"Aids Care"},{"key":"pone.0262533.ref004","article-title":"A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV","volume":"15","author":"PG Clay","year":"2018","journal-title":"Aids Res Ther"},{"issue":"2","key":"pone.0262533.ref005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170661","article-title":"Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy\u2014Results from a large french multicenter cohort study","volume":"12","author":"L Cotte","year":"2017","journal-title":"Plos One"},{"key":"pone.0262533.ref006","article-title":"Effectiveness of Single- vs MultipleTablet Regimens as First-Line ART in ICONA Cohort","author":"A Mondi","journal-title":"CROI 20192019"},{"key":"pone.0262533.ref007","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2147\/PPA.S192735","article-title":"Adherence to HIV treatment regimens: systematic literature review and meta-analysis","volume":"13","author":"F Altice","year":"2019","journal-title":"Patient preference and adherence"},{"issue":"10","key":"pone.0262533.ref008","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1080\/09540121.2020.1736258","article-title":"Does switching from multiple to single-tablet regimen containing the same antiretroviral drugs improve adherence? A group-based trajectory modeling analysis","volume":"32","author":"S Furtado Dos Santos","year":"2020","journal-title":"Aids Care"},{"issue":"1","key":"pone.0262533.ref009","doi-asserted-by":"crossref","DOI":"10.1186\/s12981-020-00268-1","article-title":"Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries","volume":"17","author":"J Cohen","year":"2020","journal-title":"Aids Res Ther"},{"issue":"7","key":"pone.0262533.ref010","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/jac\/dkv083","article-title":"Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database","volume":"70","author":"F Raffi","year":"2015","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"1","key":"pone.0262533.ref011","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12916-016-0640-4","article-title":"Beyond viral suppression of HIV\u2014the new quality of life frontier.","volume":"14","author":"JV Lazarus","year":"2016","journal-title":"BMC medicine"},{"key":"pone.0262533.ref012","first-page":"115","article-title":"One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects","volume":"4","author":"M Airoldi","year":"2010","journal-title":"Patient preference and adherence"},{"issue":"7","key":"pone.0262533.ref013","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(14)70782-0","article-title":"Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial","volume":"14","author":"JR Arribas","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"pone.0262533.ref014","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1080\/09540121.2019.1576841","article-title":"Health-related quality of life among HIV-infected patients initiating treatment in Brazil in the single-tablet regimen era","volume":"31","author":"JO Costa","year":"2019","journal-title":"Aids Care"},{"key":"pone.0262533.ref015","first-page":"9","article-title":"Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting.","volume":"10","author":"GL Colombo","year":"2014","journal-title":"Therapeutics and clinical risk management"},{"key":"pone.0262533.ref016","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/CEOR.S38977","article-title":"Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen.","volume":"5","author":"GL Colombo","year":"2013","journal-title":"ClinicoEconomics and outcomes research: CEOR"},{"key":"pone.0262533.ref017","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2147\/CEOR.S24130","article-title":"Cost-effectiveness analysis of initial HIV treatment under Italian guidelines","volume":"3","author":"GL Colombo","year":"2011","journal-title":"ClinicoEconomics and outcomes research: CEOR"},{"issue":"1","key":"pone.0262533.ref018","doi-asserted-by":"crossref","first-page":"e0147821","DOI":"10.1371\/journal.pone.0147821","article-title":"Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States","volume":"11","author":"DE Sweet","year":"2016","journal-title":"Plos One"},{"issue":"8","key":"pone.0262533.ref019","doi-asserted-by":"crossref","first-page":"e0182007","DOI":"10.1371\/journal.pone.0182007","article-title":"Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients","volume":"12","author":"N Gianotti","year":"2017","journal-title":"Plos One."},{"issue":"1","key":"pone.0262533.ref020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40360-018-0252-z","article-title":"Efficacy and safety of the switch of Triumeq(R) to generic (abacavir + lamivudine) + Tivicay(R): data at 24 weeks","volume":"19","author":"J Olalla","year":"2018","journal-title":"BMC pharmacology & toxicology"},{"issue":"4","key":"pone.0262533.ref021","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/fcp.12363","article-title":"Comparison of adherence to generic multi-tablet regimens vs. brand multi-tablet and brand single-tablet regimens likely to incorporate generic antiretroviral drugs by breaking or not fixed-dose combinations in HIV-infected patients","volume":"32","author":"J Rwagitinywa","year":"2018","journal-title":"Fund Clin Pharmacol"},{"issue":"4","key":"pone.0262533.ref022","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/QAI.0000000000000199","article-title":"Effectiveness of antiretroviral therapy in individuals who for economic reasons were switched from a once-daily single-tablet regimen to a triple-tablet regimen","volume":"66","author":"FN Engsig","year":"2014","journal-title":"Journal of acquired immune deficiency syndromes (1999)"},{"issue":"2)","key":"pone.0262533.ref023","doi-asserted-by":"crossref","first-page":"84","DOI":"10.7326\/0003-4819-158-2-201301150-00002","article-title":"Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States","volume":"158","author":"RP Walensky","year":"2013","journal-title":"Ann Intern Med"},{"issue":"10","key":"pone.0262533.ref024","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7326\/0003-4819-158-10-201305210-00015","article-title":"Cost-effectiveness of generic antiretroviral therapy","volume":"158","author":"G Hirnschall","year":"2013","journal-title":"Ann Intern Med"},{"issue":"4","key":"pone.0262533.ref025","doi-asserted-by":"crossref","first-page":"19497","DOI":"10.7448\/IAS.17.4.19497","article-title":"Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014\u20132018","volume":"17","author":"A Hill","year":"2014","journal-title":"J Int Aids Soc"},{"issue":"3","key":"pone.0262533.ref026","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/hiv.12097","article-title":"Antiretroviral treatment-based cost saving interventions may offset expenses for new patients and earlier treatment start","volume":"15","author":"C Angeletti","year":"2014","journal-title":"Hiv Med"},{"key":"pone.0262533.ref027","first-page":"27","article-title":"Consumption of antiretroviral used in HIV and associated expenditures in Europe during the last ten years: Impact of recent generic antiretroviral on cost reduction.","volume":"31","author":"J Rwagitinywa","year":"2017","journal-title":"Fund Clin Pharmacol"},{"issue":"9","key":"pone.0262533.ref028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023946","article-title":"Calculation of Direct Antiretroviral Treatment Costs and Potential Cost Savings by Using Generics in the German HIV ClinSurv Cohort","volume":"6","author":"M Stoll","year":"2011","journal-title":"Plos One"},{"issue":"2","key":"pone.0262533.ref029","first-page":"466","article-title":"Physicians\u2019 opinions on generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection: a multicentre survey in Spain","volume":"75","author":"I Suarez-Garcia","year":"2020","journal-title":"J Antimicrob Chemoth"},{"key":"pone.0262533.ref030","first-page":"55","article-title":"Use of generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection in Spain.","volume":"23","author":"MR Alguero","year":"2020","journal-title":"J Int Aids Soc"},{"issue":"2","key":"pone.0262533.ref031","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40801-016-0070-9","article-title":"Patients\u2019 Willingness to Take Multiple-Tablet Antiretroviral Therapy Regimens for Treatment of HIV","volume":"3","author":"EA Engelhard","year":"2016","journal-title":"Drugs\u2014real world outcomes."},{"key":"pone.0262533.ref032","doi-asserted-by":"crossref","first-page":"2325958218822304","DOI":"10.1177\/2325958218822304","article-title":"Desimplification of Single Tablet Antiretroviral (ART) Regimens-A Practical Cost-Savings Strategy?","volume":"18","author":"H Krentz","year":"2019","journal-title":"Journal of the International Association of Providers of AIDS Care"},{"issue":"2","key":"pone.0262533.ref033","doi-asserted-by":"crossref","first-page":"e0117214","DOI":"10.1371\/journal.pone.0117214","article-title":"Perception of antiretroviral generic medicines: one-day survey of HIV-infected patients and their physicians in France","volume":"10","author":"C Jacomet","year":"2015","journal-title":"Plos One"},{"key":"pone.0262533.ref034","volume-title":"90-90-90. An ambitious treatment target to help end the AIDS epidemic.","author":"UNAIDS","year":"2014"},{"key":"pone.0262533.ref035","article-title":"Epidemiologie van aids en hiv-infectie in Belgi\u00eb\u2014Toestand op 31 december 2019","author":"A Sasse","year":"2020","journal-title":"Sciensano"},{"key":"pone.0262533.ref036","article-title":"Needs survey among people with HIV","author":"G Scheerder","year":"2020","journal-title":"Antwerp"},{"issue":"6","key":"pone.0262533.ref037","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1018451930750","article-title":"Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV).","volume":"6","author":"AW Wu","year":"1997","journal-title":"Qual Life Res"},{"issue":"4","key":"pone.0262533.ref038","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0895-4356(98)00163-2","article-title":"The effect of adding a cognitive dimension to the EuroQol multiattribute health-status classification system","volume":"52","author":"PFM Krabbe","year":"1999","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"pone.0262533.ref039","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1023\/A:1013050904635","article-title":"Validation of the HIV treatment satisfaction questionnaire (HIVTSQ)","volume":"10","author":"A Woodcock","year":"2001","journal-title":"Qual Life Res."},{"issue":"9","key":"pone.0262533.ref040","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/QAD.0b013e3283354a7b","article-title":"Cognitive dysfunction in HIV patients despite long-standing suppression of viremia","volume":"24","author":"S Simioni","year":"2010","journal-title":"Aids"},{"issue":"7","key":"pone.0262533.ref041","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/09540120500465160","article-title":"The CASE adherence index: A novel method for measuring adherence to antiretroviral therapy","volume":"18","author":"SB Mannheimer","year":"2006","journal-title":"Aids Care"},{"key":"pone.0262533.ref042","author":"AT Beck","year":"2002","journal-title":"Beck Depression Inventory II"},{"key":"pone.0262533.ref043","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/S0895-4356(01)00449-8","article-title":"Development and validation of a self-completed HIV symptom index","volume":"54","author":"AC Justice","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"pone.0262533.ref044","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-017-0442-1","article-title":"When and how should multiple imputation be used for handling missing data in randomised clinical trials\u2014a practical guide with flowcharts","volume":"17","author":"JC Jakobsen","year":"2017","journal-title":"Bmc Med Res Methodol"},{"issue":"2","key":"pone.0262533.ref045","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1089\/apc.2009.0259","article-title":"Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF","volume":"24","author":"SL Hodder","year":"2010","journal-title":"AIDS Patient Care STDS"},{"issue":"2","key":"pone.0262533.ref046","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QAI.0b013e3181a572cf","article-title":"Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients","volume":"51","author":"E Dejesus","year":"2009","journal-title":"Journal of acquired immune deficiency syndromes"},{"issue":"5","key":"pone.0262533.ref047","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s13365-020-00870-z","article-title":"Lifetime antiretroviral exposure and neurocognitive impairment in HIV","volume":"26","author":"P Amusan","year":"2020","journal-title":"J Neurovirol"},{"key":"pone.0262533.ref048","unstructured":"European AIDS Clinical Society (EACS). EACS Guidelines 10.0. 2020."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0262533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,22]],"date-time":"2023-01-22T21:54:54Z","timestamp":1674424494000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0262533"}},"subtitle":[],"editor":[{"given":"Evy","family":"Yunihastuti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0262533","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]}}}